Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-beta2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research.
CAS Number:
[285985-06-0]
Target:
TGF-beta/Smad
* VAT and and shipping costs not included. Errors and price changes excepted